Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Janux Therapeutics, Inc. - Common Stock (NQ: JANX )

36.37 -0.80 (-2.15%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Janux Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Announces Proposed Public Offering
From Janux Therapeutics
Via Business Wire
Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
From Janux Therapeutics
Via Business Wire
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Announces Updates to Board of Directors
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Announces Proposed Public Offering of Common Stock
From Janux Therapeutics
Via Business Wire
Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors
From Janux Therapeutics
Via Business Wire
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics to Present at Upcoming Investor Conferences in November
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources
From Janux Therapeutics, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.